Clinical outcome of levonorgestrel intra-uterine system in idiopathic menorrhagia

European Review for Medical and Pharmacological Sciences

Volumn 15, Issue 7, 2011, Pages 764-768

  Chattopdhyay, B ^a   Nigam, Aruna ^a   Goswami, S ^b   Chakravarty, P S ^b  

^a LADY HARDINGE MEDICAL COLLEGE   (India)

^b MEDICAL COLLEGE AND HOSPITAL   (India)

Author keywords

Anemia; Levonorgestrel intrauterine system; Menorrhagia

Indexed keywords

LEVONORGESTREL; BIOLOGICAL MARKER; CONTRACEPTIVE AGENT; HEMOGLOBIN;

ACNE; ADULT; ARTICLE; BLEEDING; BREAST TENDERNESS; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; EDEMA; FEMALE; FOLLOW UP; HEADACHE; HUMAN; IDIOPATHIC MENORRHAGIA; MENORRHAGIA; MENSTRUAL IRREGULARITY; PELVIS PAIN SYNDROME; PROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; UTERUS PERFORATION; VAGINA BLEEDING; WEIGHT GAIN; BLOOD; CHI SQUARE DISTRIBUTION; DEVELOPING COUNTRY; DRUG EFFECT; INDIA; INTRAUTERINE CONTRACEPTIVE DEVICE; INTRAVAGINAL DRUG ADMINISTRATION; MENSTRUATION; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PATIENT SATISFACTION; TIME;

ADMINISTRATION, INTRAVAGINAL; ADULT; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; CONTRACEPTIVE AGENTS, FEMALE; DEVELOPING COUNTRIES; FEMALE; HEMOGLOBINS; HUMANS; INDIA; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; MENORRHAGIA; MENSTRUATION; MIDDLE AGED; PATIENT SATISFACTION; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 79961179447     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. NATIONAL FAMILY HEALTH SURVEY, India. www.nfhsindia.org/pdf/India.pdf
2. KRIPLANI A SINGH BM, LAL S, AGARWAL N. Efficacy, acceptability and side effects of the levonorgestrel intrauterine system for menorrhagia. Int J Gynaecol Obstet 2007; 97: 190-194.
3. XIAO B, WU SC, CHONG J, ZENG T, HAN LH, LUUKKAINEN T. Therapeutic effects of LNG IUS in the treatment of idiopathic menorrhagia. Fertil Steril 2003; 79: 963-969.
4. BARRINGTON JW, BOWEN-SIMPKINS P. The levonorgestrel intrauterine system in the management of menorrhagia. Br J Obstet Gynecol 1997; 104: 614-616.
5. CAMERON IT. The levonorgestrel intrauterine system: the benefits of reduced bleeding. Eur J Contracept Reprod Health Care 2001; 6: 27-32.
6. PHILLIPS V, GRAHAM CT, MANEK S, MCCLUGGAGE WG. The effect of levonorgestrel intrauterine system (Mirena coil) on endometrial morphology. J Clin Pathol 2003; 56: 305-307.
7. RUTANEN EM, SALMI A NYMAN T. mRNA expression of insulin like growth factors (IGF-1) is suppressed and those of IGF-2 and IGF-Binding Protein-1 are constantly expressed in endometrium during the use of an intra uterine levonorgestrel system. Mol Hum Reprod 1997; 3: 749-754.
8. JENSEN, JEFFREY T. Contraceptive and therapeutic effects of levonorgestrel intrauterine system: an overview. Obstet Gynecol Surv 2005; 60: 604-612
9. OLIVEIRA-RIBEIRO M, PETTA CA, DE ANGELO ANDRADE LA, BAHAMONDES L, HIDALGO MM. Correlation between endometrial histology, microvascular density and calibre, matrix metalloproteinase-3 and bleeding pattern in women using a levonorgestrel-releasing intrauterine system. Hum Reprod 2004; 19: 1778-1784.